Editorial: Cancer Nanotheranostics: What Have We Learned So Far? by Conde, J. et al.
EDITORIAL
published: 06 January 2016
doi: 10.3389/fchem.2015.00071
Frontiers in Chemistry | www.frontiersin.org 1 January 2016 | Volume 3 | Article 71
Edited and reviewed by:
Gil Garnier,
Bioresource Processing Research
Institute of Australia, Australia
*Correspondence:
João Conde
jdconde@mit.edu;
conde.bio@gmail.com
Specialty section:
This article was submitted to
Chemical Engineering,
a section of the journal
Frontiers in Chemistry
Received: 03 November 2015
Accepted: 15 December 2015
Published: 06 January 2016
Citation:
Conde J, Tian F, de la Fuente JM and
Baptista PV (2016) Editorial: Cancer
Nanotheranostics: What Have We
Learned So Far? Front. Chem. 3:71.
doi: 10.3389/fchem.2015.00071
Editorial: Cancer Nanotheranostics:
What Have We Learned So Far?
João Conde 1, 2*, Furong Tian 3, Jesus M. de la Fuente 4 and Pedro V. Baptista 5
1Harvard-MIT Division for Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts
Institute of Technology, Cambridge, MA, USA, 2 School of Engineering and Materials Science, Queen Mary University of
London, London, UK, 3 School of Food Science and Environmental Health, College of Sciences and Health, Dublin Institute
of Technology, Dublin, Ireland, 4 Instituto de Ciencia de Materiales de Aragón, Consejo Superior de Investigaciones
Científicas/Universidad de Zaragoza, Zaragoza, Spain, 5 Research Unit on Applied Molecular Biosciences (UCIBIO),
Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Lisboa, Portugal
Keywords: oncology, cancer, nanotechnology, nanotheranostics, nanomaterials, nanoparticles
The Editorial on the Research Topic
Cancer Nanotheranostics: What HaveWe Learned So Far?
According to the National Cancer Institute, in 2015 an estimated of 1.7 million new cases of cancer
will be diagnosed only in the United States and around 600,000 people will die from the disease.
The most common type of cancer is breast cancer, with more than 234,000 new cases expected in
the United States in 2015. The next most common cancers are prostate cancer and lung cancer.
After a quarter of century of rapid technological advances, research has revealed the complexity
of cancer, a disease intimately related to the dynamic transformation of the genome. These
transformations trigger a range of modification to cell processes and molecular events that initiate
and promote tumor genesis and progression, then local invasion and metastasis, i.e., the hallmarks
of cancer development. These alterations may cause a wide scope of “diseases” that share similar
molecular patterns that cause transformation and malignancy. Each of this stepwise evolution of
the initial molecular event drives abnormal growth and loss of differentiation that ultimately causes
tissue and organ failure. The initial molecular event may lay within the erroneous expression of a
given gene, epigenetic modification and/or sporadic mutations occurring on genomic DNA during
the life span of organisms. Each and every one of these molecular events may be evaluated and
used as diagnostics biomarker and therapeutic target. For example, therapy action may target a
mutated gene and silence its expression so as to avoid erroneous protein expression that mutates
cell function. However, the full understanding of the molecular onset of this disease is still far from
achieved and the search for mechanisms of treatment will follow closely.
It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat
cancer. Today, Nanotechnology is a burgeoning field that is helping to address critical global
problems from cancer treatment to climate change. In fact, Nanotechnology is everywhere and
is everyday practice (Conde), offering numerous tools to diagnose and treat cancer, such as
new imaging agents, multifunctional devices capable of overcome biological barriers to deliver
therapeutic agents directly to cells and tissues involved in cancer growth andmetastasis, and devices
capable of predicting molecular changes to prevent action against precancerous cells (Conde et al.,
2012). The novel physical properties of inorganic particles at the nanometer size scale, combined
with the high specific surface of polymeric nanoparticles and the possibility to engineer stimuli-
respond drug release strategies, have provided new tools to physicians for the diagnostic and the
therapy of diseases such as cancer.
Nanomaterials-based delivery systems in Theranostics (Diagnostics and Therapy), at the same
size level of proteins, DNA or RNA, provide better penetration of therapeutic and diagnostic
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substances within the body at a reduced risk in comparison to
conventional therapies. At the present time, there is a growing
need to enhance the capability of theranostics procedures where
innovative multifunctional nanocarriers for cancer theranostics
may allow the development of diagnostics systems such as
colorimetric and immunoassays, and in therapy approaches
through gene therapy, drug delivery and tumor targeting systems
in cancer (Conde et al., 2014).
Some of the thousands and thousands of published
nanosystems so far will most likely revolutionize our
understanding of biological mechanisms and push forward the
clinical practice through their integration in future diagnostics
platforms. Nevertheless, despite the significant efforts toward
the use of nanomaterials in biologically relevant research, more
in vivo studies are needed to assess the applicability of these
materials as delivery agents. In fact, only a few have gone through
feasible clinical trials. Nanomaterials have to serve as the norm
rather than an exception in the future conventional cancer
treatments. Future in vivo work will need to carefully consider
the correct choice of chemical modifications to incorporate into
the multifunctional nanocarriers to avoid activation off-target,
side effects and toxicity.
It is imperious to learn how advances in nanosystems’
capabilities are being used to identify new diagnostic and
therapy apparatuses driving the development of personalized
and precision medicine in cancer therapy and diagnostics; learn
how incorporating cancer research and nanotechnology can help
patient life quality; identify how to decipher nanotheranostics
data into a real clinical strategy; and, last but not least, learn what
methods are showing fertile results in turning promising clinical
data into treatment realities (Conde et al., 2014).
Although all studies described in this Topic provide a baseline
level of data in support of the effectiveness and safety of
nanomaterials, we wonder what have we learned so far?
Current trends in biomedicine have been focused toward the
use of new materials capable to address particular and individual
characteristics in strategies for molecular precision therapies.
In this endeavor, nanoparticles have allowed a tremendous leap
forward in combining diagnostics and therapy in a single system
and doing so at the nanoscale. Nanotheranostics have enabled
the integration of targeting, imaging and therapeutics in a
single platform, with proven applicability on the management of
heterogeneous diseases.
Despite the plethora of proposed systems, only but a few
products are currently included clinical trials and much remains
to be done to allow effective clinical translation of these
promising nanotheranostics platforms.
Several nanoconjugates have been proposed, varying in
material, size and shape; some bringing current therapeutic
approaches to the nanometer scale while others enact disruptive
properties only possible by combination of different molecules
and chemistries at the nanoscale (Conde et al.). For example,
achieving controlled cellular responses of nanoparticles is critical
for the successful development and translation of NP-based
drug delivery systems. Conde et al. and Hong et al. (Pearson
et al.) reported a complete survey on the most important factors
for careful design of nanoparticles and the demand for precise
control over the physicochemical and biological properties of
NPs.
Liu et al. discuss the potential of star shaped nanoparticles
in novel imaging approaches and strategies combining therapy
and imaging in cancer. In fact, the potential of application of
nanoconjugates in enhanced imaging strategies and platforms is
discussed by Alcantara et al. with particular emphasis in current
trends in molecular imaging for optimized management of breast
cancer.
Theranostics of brain diseases such as brain cancer, is a
daunting challenge due to the unique environment of central
nervous system (Bhaskar et al., 2010). Yet passing the blood-
brain barrier (BBB) is particularly difficult. The proper design
of such engineered “nanocarriers” becomes very important
in translocating the impermeable membranes of the brain to
facilitate drug delivery. At the same time, it is also required
to retain the drug stability and ensure that early degradation
of drugs from the nanocarriers does not take place. In fact,
Mahmoudi and Hadjipanayis reported a great opinion piece
about the application of magnetic nanoparticles (MNPS) for the
treatment of brain tumors and how MNPs will likely assume a
larger role in brain cancer treatment in combination with other
adjuvant therapies.
Talking about other adjuvant therapies, radiation and gene
therapy have also gained momentum in the last years when using
nanomaterials for cancer therapy. Cooper et al. reported how
radiation therapy is one of the most commonly used treatments
for cancer and which directions to follow for the future based on
current state of nanoparticle-assisted radiation therapy.
Regarding gene therapy, Moreno and Pego reported a critical
overview of using therapeutic antisense oligonucleotides against
cancer and how difficult has been to get to the clinic. This is
in fact not only a problem with gene therapy but a universal
issue as whilst many pre-clinical data has been generated, a lack
of understanding still exists on how to efficiently tackle all the
different challenges presented for cancer targeting in a clinical
setting.
Perhaps another interesting avenue in cancer
nanotheranostics is the interfering effect of the immune
system in the efficacy of proposed platforms. In fact, a clear
perspective on the interaction between immune response and
immune modulators is still missing from the general picture
of nanotheranostics, not only in what concerns the organisms
response to the systemic delivery of nanoconjugates that may
hamper efficacy, but also the use of the immune response and
nanoconjugates interaction with immune system as means to
achieve higher and more directed/targeted therapy to the cancer
site. As such, the effect and response of diverse properties of
nanodiagnostics platforms in the organisms have been discussed
by Clift et al. where nanoconjugates are discussed in terms
of the immune response triggered after systemic delivery;
whereas Conniot et al. and Pearson et al. (Dawidczyk et al.) have
demonstrated how nanotheranostics may use and profit from
the specific and unspecific immune response to enhance efficacy.
Actually, cancer immunotherapy is nowadays consider a hot
topic and a huge breakthrough in modern Science (Conde et al.,
2015).
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Gene expression has been targeted for silencing to avoid
mutated protein function to exert its role in tumor progression.
Nanotechnology based systems shows great promise in
addressing novel genomic biomarkers that signal cancer cells,
and do it with increased sensitivity that allow early detection
of genome/genetic modifications that at the origin of cancer.
Emergent technologies have been combined with nanoscale
structures for directing to the site of interest with decreased side
effects. The experience gathered thus far has shown that the
next step in the effective translation of nanotheranostics into
the clinics relates to the body’s response to the nanoconjugates.
What are the toxicity impacts of these devices and platforms?
Are there enough data for the full chronic toxicity evaluation of
the application of these systems? Is the immune system a friend
or foe for nanotheranostics?
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